Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug

Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China

Fineline Cube Sep 14, 2023

Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...

Policy / Regulatory

NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds

Fineline Cube Sep 14, 2023

The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve...

Company Drug

MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies

Fineline Cube Sep 13, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...

Company Deals

Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline

Fineline Cube Sep 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...

Company Deals

Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine

Fineline Cube Sep 13, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...

Company Drug

Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...

Company Drug

AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial

Fineline Cube Sep 13, 2023

AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...

Company Deals

Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion

Fineline Cube Sep 13, 2023

China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...

Policy / Regulatory

NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time

Fineline Cube Sep 13, 2023

The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...

Company Medical Device

Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review

Fineline Cube Sep 13, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4

Fineline Cube Sep 13, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...

Company Drug

Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment

Fineline Cube Sep 13, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development

Fineline Cube Sep 13, 2023

China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...

Company Deals

Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO

Fineline Cube Sep 13, 2023

Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...

Company Deals

Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091

Fineline Cube Sep 13, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...

Company Medical Device

Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring

Fineline Cube Sep 13, 2023

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...

Company Drug

Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China

Fineline Cube Sep 12, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland...

Company Drug

HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China

Fineline Cube Sep 12, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...

Company Drug

Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA

Fineline Cube Sep 12, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...

Posts pagination

1 … 526 527 528 … 718

Recent updates

  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
  • NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Company Deals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.